Innovate UK has released £1M to fund a further next generation development of Abingdon Health’s lateral-flow rapid test readout technology; AppDx®.
Abingdon Health spoke with a leading virologist about why nucleic acid lateral flow assays are vital for deploying decentralised molecular tests.
Abingdon Health is mobilising its rapid test operations in response to the COVID-19 outbreak and recruiting in several areas. Learn more.
Learn how our multi-disciplinary approach and precision manufacturing assures security of supply for the most complex of assays and markets
September 17, 2020